Oncimmune Holdings plc (LON:ONC) has entered a commercial partnership with US West Coast biotech, Augmenta Bioworks, to profile patient plasma samples and characterise antibody therapeutic candidates discovered via Augmenta’s proprietary..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a new master service agreement with Augmenta Bioworks, Inc. to profile patient plasma samples and..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has given notice that its Annual General Meeting will be held at 10:00 am on 30 November 2020 at the offices..
Oncimmune Holdings plc (LON:ONC) FY 2020 was the first full year of delivery under Oncimmune’s three-year plan of operational, technical and commercial targets for products and services, accomplishing major milestones..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its unaudited results for the year ended 31st May 2020 and provides an update on recent progress. Highlights Commercial..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the initiation of a study by Biodesix Inc using Oncimmune’s EarlyCDT® Lung blood test, which is marketed in the..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that, following its announcement on 6 October that Oncimmune is being funded by the UK Government to develop a COVID-19..
Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two..
The award of funding to Oncimmune Holdings plc (LON:ONC) by the ‘UK Research and Innovation Ideas to Address COVID-19’ project, leverages its proprietary ImmunoINSIGHTS technology to help in predicting disease..
Validated research tool to be used to predict disease severity and individual therapeutic response to COVID-19 in aid of rapid vaccine and drug development Oncimmune Holdings plc (LON:ONC), the leading..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has signed a collaboration with Genentech, a member of the Roche Group, to characterise the autoantibody profiles of..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the publication by PLOS ONE of a study led by Leeds University Academic Unit of Health Economics, supported by..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling collaboration with a leading global biopharmaceutical company with extensive experience in developing novel..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the national ITV News1 feature last weekend on Oncimmune’s EarlyCDT® Lung blood test titled “New Blood Test Provides Breakthrough..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the presentation of two further abstracts connected to the Early detection of Cancer of the Lung Scotland trial. These..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that Roche has exercised its option to increase the scope and value of the cornerstone contract announced on 28..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has noted the publication of research, supported by its ImmunoINSIGHTS team, in Arthritis Research & Therapy1, entitled ‘Profiling IgG antibodies targeting..
Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that its distributor in Brazil, Valentech International LLC, has obtained marketing authorisation for the EarlyCDT Lung blood test for..
Oncimmune Holdings plc (LON:ONC), a leading global immunodiagnostics group, has today announced it has been awarded the ‘Winning in Business in Spain’ award at the Department for International Trade’s (DIT)..
